Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

This is an experimental study to evaluate the safety and efficacy of CAR T cells targeting CAIX in the treatment of advanced renal cancer.

Trial Details

NCT ID
NCT04969354
Phase
PHASE1
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • CAR-T cell immunotherapy
Locations (sample)
  • Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

  • Male or female patients aged from 18 to 70 years old;
  • The patient's ECOG score is ≤ 2;
  • Patients with advanced or metastatic renal cell carcinoma:
  • (1) have received first-line and second-line targeted therapy in the past; (2) Previous immunization with PD-1/L1 and ≤2 regimens; (3) Unable to to…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →